Fig. 1From: Role of MAML1 in targeted therapy against the esophageal cancer stem cellsSphere formation and differentiation. The first CD44+ tumor sphere was observed after 10 days (low adherent flasks) (A). Spheres were able to adhere and differentiate in the adherent flasks (B, C)Back to article page